5,345 research outputs found
Age-related hospitalization and mortality rates for acute myocardial infarction: The 1969-82 vs. the 1990-94 period
Pylephlebitis: A Systematic Review on Etiology, Diagnosis, and Treatment of Infective Portal Vein Thrombosis
Pylephlebitis, defined as infective thrombophlebitis of the portal vein, is a rare condition with an incidence of 0.37–2.7 cases per 100,000 person-years, which can virtually complicate any intra-abdominal or pelvic infections that develop within areas drained by the portal venous circulation. The current systematic review aimed to investigate the etiology behind pylephlebitis in terms of pathogens involved and causative infective processes, and to report the most common symptoms at clinical presentation. We included 220 individuals derived from published cases between 1971 and 2022. Of these, 155 (70.5%) were male with a median age of 50 years. There were 27 (12.3%) patients under 18 years of age, 6 (2.7%) individuals younger than one year, and the youngest reported case was only 20 days old. The most frequently reported symptoms on admission were fever (75.5%) and abdominal pain (66.4%), with diverticulitis (26.5%) and acute appendicitis (22%) being the two most common causes. Pylephlebitis was caused by a single pathogen in 94 (42.8%) cases and polymicrobial in 60 (27.2%) cases. However, the responsible pathogen was not identified or not reported in 30% of the included patients. The most frequently isolated bacteria were Escherichia coli (25%), Bacteroides spp. (17%), and Streptococcus spp. (15%). The treatment of pylephlebitis consists initially of broad-spectrum antibiotics that should be tailored upon bacterial identification and continued for at least four to six weeks after symptom presentation. There is no recommendation for prescribing anticoagulants to all patients with pylephlebitis. However, they should be administered in patients with thrombosis progression on repeat imaging or persistent fever despite proper antibiotic therapy to increase the rates of thrombus resolution or decrease the overall mortality, which is approximately 14%
Physical Implementation of a Tunable Memristor-based Chua's Circuit
Nonlinearity is a central feature in demanding computing applications that
aim to deal with tasks such as optimization or classification. Furthermore, the
consensus is that nonlinearity should not be only exploited at the algorithm
level, but also at the physical level by finding devices that incorporate
desired nonlinear features to physically implement energy, area and/or time
efficient computing applications. Chaotic oscillators are one type of system
powered by nonlinearity, which can be used for computing purposes. In this work
we present a physical implementation of a tunable Chua's circuit in which the
nonlinear part is based on a nonvolatile memristive device. Device
characterization and circuit analysis serve as guidelines to design the circuit
and results prove the possibility to tune the circuit oscillatory response by
electrically programming the device.Comment: Accepted by IEEE 48th European Solid State Circuits Conference
(ESSCIRC 2022
Automatic Deployment of Services in the Cloud with Aeolus Blender
International audienceWe present Aeolus Blender (Blender in the following), a software product for the automatic deployment and configuration of complex service-based, distributed software systems in the " cloud ". By relying on a configuration optimiser and a deployment planner, Blender fully automates the deployment of real-life applications on OpenStack cloud deployments , by exploiting a knowledge base of software services provided by the Mandriva Armonic tool suite. The final deployment is guaranteed to satisfy not only user requirements and relevant software dependencies , but also to be optimal with respect to the number of used virtual machines
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL
In chronic lymphocytic leukemia (CLL), Notch1 and Notch2 signaling is constitutively activated and contributes to apoptosis resistance. We show that genetic inhibition of either Notch1 or Notch2, through small-interfering RNA, increases apoptosis of CLL cells and is associated with decreased levels of the anti-apoptotic protein Mcl-1. Thus, Notch signaling promotes CLL cell survival at least in part by sustaining Mcl-1 expression. In CLL cells, an enhanced Notch activation also contributes to the increase in Mcl-1 expression and cell survival induced by IL-4.Mcl-1 downregulation by Notch targeting is not due to reduced transcription or degradation by caspases, but in part, to increased degradation by the proteasome. Mcl-1 downregulation by Notch targeting is also accompanied by reduced phosphorylation of eukaryotic translation initiation factor 4E (eIF4E), suggesting that this protein is another target of Notch signaling in CLL cells.Overall, we show that Notch signaling sustains CLL cell survival by promoting Mcl-1 expression and eIF4E activity, and given the oncogenic role of these factors, we underscore the therapeutic potential of Notch inhibition in CLL
A new hyaluronic acid pH sensitive derivative obtained by ATRP for potential oral administration of proteins
Diverticular Disease and Rifaximin: An Evidence-Based Review
There have been considerable advances in the treatment of diverticular disease in recent years. Antibiotics are frequently used to treat symptoms and prevent complications. Rifaximin, a non-absorbable antibiotic, is a common therapeutic choice for symptomatic diverticular disease in various countries, including Italy. Because of its low systemic absorption and high concentration in stools, it is an excellent medicine for targeting the gastrointestinal tract, where it has a beneficial effect in addition to its antibacterial properties. Current evidence shows that cyclical rifaximin usage in conjunction with a high-fiber diet is safe and effective for treating symptomatic uncomplicated diverticular disease, while the cost-effectiveness of long-term treatment is unknown. The use of rifaximin to prevent recurrent diverticulitis is promising, but further studies are needed to confirm its therapeutic benefit. Unfortunately, there is no available evidence on the efficacy of rifaximin treatment for acute uncomplicated diverticulitis
- …